Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.
Journal of Affective Disorders December 1, 2022 Adrienne Lapidos, Daniela Lopez-Vives, Cortney E. Sera et al.
BACKGROUND Intravenous (IV) ketamine is an effective therapy for treatment-resistant depression. A large data base is confirmatory and steadily expanding. Qualitative studies can inform best practices and suggest new research directions. As part of a clinical trial designed to identify biomarkers of ketamine response, a qualitative study was conducted to characterize experiences with: receiving...